产品说明书
Telbivudine
 |
同义名 : | NV 02B;Epavudine;Tyzeka;LDT 600;β-L-Thymidine;L-Deoxythymidine;2'-deoxy-L-Thymidine;L-Thymidine |
| CAS号 : | 3424-98-4 | |
| 货号 : | A158594 | |
| 分子式 : | C10H14N2O5 | |
| 纯度 : | 98% | |
| 分子量 : | 242.229 | |
| MDL号 : | MFCD02683612 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(206.42 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 30 mg/mL(123.85 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Telbivudine, an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication[3]. Telbivudine reverses B19V-induced dysregulation of BIRC3 (Baculoviral Inhibitor of apoptosis Repeat-Containing protein 3), thus, intervening in the apoptosis pathway and protecting susceptible cells from cell death[4]. Telbivudine given for 4 weeks resulted in an 8-log reduction of woodchuck hepatitis virus DNA, and a 3.8-log reduction of hepatitis B virus DNA in human. After 52 weeks of telbivudine treatment there was an approximate 6-log reduction of hepatitis B virus DNA levels, hepatitis B virus DNA became undetectable by PCR assay in 61% of patients. Its antiviral efficacy is significantly better than lamivudine[5]. In vitro assays revealed that telbivudine treatment induced TGF-β1 expression in human macrophagic cells. Telbivudine treatment enhanced the proportion of serum IgG-Fc agalactosylation in cirrhotic patients, which was associated with enhanced levels of TGF-β1 and IgG[6]. Telbivudine exerts endothelial-protective effects in B19V-infected endothelial cells and improves chronic myocarditis associated with B19V transcriptional activity[7]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.13mL 0.83mL 0.41mL |
20.64mL 4.13mL 2.06mL |
41.28mL 8.26mL 4.13mL |
| 参考文献 |
|---|